2.11 USD
↗ 0.19 (9.90%)AT CLOSE (11:59 AM EDT)
ALX Oncology Holdings Inc. Common Stock
ALXONASDAQ • USD
2.15
↗ 0.04 (1.66%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
2.15
↗ 0.04 (1.66%)
Market: CLOSED
ALX Oncology Holdings Inc. Common Stock (ALXO) trades at $2.13 per share. ALXO shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics suggest ALXO is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Aug 6, 2026.
Open?$1.94
High?$2.14
Low?$1.87
Prev. Close?$1.92
Volume?580.9K
Avg. Volume?1.3M
VWAP?$2.02
Rel. Volume?0.44x
Bid / Ask
Bid?$1.81 × 100
Ask?$2.85 × 100
Spread?$1.04
Midpoint?$2.33
Valuation & Ratios
Market Cap?258.4M
Shares Out?134.6M
Float?88.9M
Float %?66.0%
P/E Ratio?N/A
P/B Ratio?1.71
EPS?-$0.66
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Employees
43
Market Cap
258.4M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2020-07-17
Address
323 ALLERTON AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-466-7125
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-466-7125
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?1
Momentum?65
Short Sent.?24
Piotroski F-Score?0/9Weak
Altman Z-Score?-0.91Distress
Confidence?51%Low
Short InterestHigh
Short % of Float?8.40%Elevated
Short Interest?7.5M
Days to Cover?6.6
Free Float88.9M
Avg Daily Volume1.1M
Settlement Date2026-07-15
Financial Health
Current Ratio?7.21Strong
Quick Ratio?7.21Strong
Cash Ratio?1.60Strong
Debt/Equity?0.06Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.71CHEAP▾
Peers100
S&P82
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-2.7CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-58.7%WEAK▾
S&P3
ROA?-49.8%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-78329000
Enterprise Value?$234.6M
Fundamentals ratios updated end of day